Sequencing treatment in prostate cancer: the logic at every step.

Step 1 · Localised disease: surveillance, surgery or radiation

When prostate cancer is caught while still confined to the gland, the first job is to decide whether and how to treat it. That depends on risk — estimated from the PSA, the Gleason grade (ISUP grade group) and the clinical stage — which sorts disease into low, intermediate (favourable or unfavourable) and high risk.[4] There are three roads: active surveillance (close monitoring with PSA, MRI and repeat biopsy, treating only if the cancer shows signs of progressing), radical prostatectomy (surgery to remove the gland), and radiotherapy (external-beam radiation or brachytherapy, with hormone therapy added for higher-risk disease).

The most important thing to understand is how close the long-term results are. In the ProtecT trial, 1,643 men with localised, PSA-detected cancer were randomly assigned to monitoring, surgery or radiotherapy and followed for a median of 15 years. Death from prostate cancer was low in every group — about 2.7% overall (3.1% with monitoring, 2.2% with surgery, 2.9% with radiotherapy), with no significant difference between them. Radical treatment did reduce the chance of the cancer progressing or spreading (roughly 4% developed metastases after surgery or radiation versus 7% with monitoring), but it did not lower the chance of dying from prostate cancer. Almost a quarter of the men on monitoring were alive at 15 years without ever needing treatment.[3]

One sequencing detail matters here. If the PSA rises after surgery, early salvage radiotherapy — given when the PSA first climbs — gives the same cancer control as routinely irradiating every high-risk man straight after surgery, while sparing many the side effects. So radiation is generally held in reserve and used promptly if needed, rather than given to everyone up front.[4]

Step 2 · Biochemical recurrence: a rising PSA, nothing visible

After surgery or radiation, the PSA is watched. If it starts to climb but scans show no metastases, this is biochemical recurrence — a signal that some cancer remains, found long before it would ever be felt. The response depends on the first treatment and on how fast the PSA is rising. After surgery, salvage radiotherapy to the prostate bed, sometimes with a short course of hormone therapy, can still be curative. After radiation, the salvage options are narrower and chosen carefully.

When the recurrence is high-risk — in particular a short PSA doubling time — the EMBARK trial showed that adding the hormonal agent enzalutamide (with or without standard androgen-deprivation therapy) delayed the appearance of metastases compared with hormone therapy alone.[10] Increasingly, a PSMA-PET scan is used at this point: it can pinpoint where the cancer has come back when ordinary scans are blank, which sometimes allows targeted treatment of a single spot and sometimes reveals that the disease is already more widespread than thought.

Step 3 · Metastatic hormone-sensitive disease: intensify early

When prostate cancer has spread but still responds to lowering testosterone, it is called metastatic hormone-sensitive (or castration-sensitive) prostate cancer. The backbone of treatment is androgen-deprivation therapy (ADT) — medical or surgical castration. For decades that was all that was offered. It is no longer enough on its own, and this is where the “intensify early” principle is strongest.

The modern standard is to add at least one more agent from the start:

• A doublet — ADT plus one androgen-receptor pathway inhibitor (abiraterone, enzalutamide or apalutamide). Across the LATITUDE, TITAN, ENZAMET and ARCHES trials, adding one of these agents to ADT improved survival, and a doublet is appropriate for most men.[6]
• A triplet — ADT plus docetaxel chemotherapy plus a hormonal agent. In ARASENS, adding darolutamide to ADT and docetaxel reduced the risk of death by about 32% (hazard ratio 0.68); in PEACE-1, adding abiraterone to ADT and docetaxel improved survival as well.[7][8]

The role of chemotherapy here traces back to CHAARTED, which first showed that adding docetaxel to ADT lengthened survival — a median of 57.6 versus 44.0 months — with the benefit concentrated in men with high-volume disease (visceral metastases, or four or more bone lesions with at least one beyond the spine and pelvis).[5] Triplets, which add that chemotherapy on top of a hormonal agent, are therefore generally reserved for fitter men with high-volume or de novo (present-at-diagnosis) metastatic disease, where the extra intensity pays off. Doublets suit most others.

A newer wrinkle: for men whose cancer carries a BRCA2 mutation, a PARP inhibitor (niraparib) combined with abiraterone was approved in late 2025 for use even at this hormone-sensitive stage — an early sign that genetic testing is starting to shape treatment earlier in the journey, not only at the end.[1]

Step 4 · Non-metastatic castration-resistant disease

Sometimes the PSA begins to rise despite castrate testosterone levels, yet ordinary scans still show no metastases. This in-between state — non-metastatic castration-resistant prostate cancer — matters most when the PSA is doubling quickly (in under ten months), which signals a higher risk of metastases soon. Three trials — SPARTAN (apalutamide), PROSPER (enzalutamide) and ARAMIS (darolutamide) — each showed that adding one of these hormonal agents to ADT delayed the appearance of metastases and improved survival compared with ADT alone.[9]

This state is also being redrawn by imaging. A PSMA-PET scan frequently finds metastases that conventional scans miss, so a number of men once labelled “non-metastatic” are now recognised as already metastatic — and treated accordingly.

Step 5 · Metastatic castration-resistant disease: the menu and the logic

When the cancer spreads and grows despite castration, treatment enters its most complex phase. There are many options, and — in the words of the guidelines — the best sequence is still evolving.[2] Rather than a fixed order, the choice at each step is steered by a handful of principles.

Let biology choose. Guidelines now strongly recommend testing the tumour, and the man, for genetic changes — inherited and acquired faults in DNA-repair genes (HRR, including BRCA), and mismatch-repair deficiency or microsatellite instability.[1] These results open specific doors: a PARP inhibitor for HRR/BRCA-altered disease (as in the PROfound trial of olaparib), and the immunotherapy pembrolizumab for the small group with mismatch-repair-deficient or microsatellite-unstable tumours.[17]

Switch the mechanism; do not repeat it. This is the single most important sequencing lesson at this stage. The hormonal agents all work through the same androgen-receptor pathway, so swapping one for another after the first fails rarely helps. The CARD trial tested exactly this: in men who had already had docetaxel and one hormonal agent, switching to chemotherapy (cabazitaxel) beat trying a second hormonal agent — median survival 13.6 versus 11.0 months, and only about 14% of men responded to that second hormonal agent versus 36% on chemotherapy.[11] Guidelines now explicitly advise against using two androgen-receptor agents back to back.[1]

With those principles in mind, the menu of life-prolonging options — each with a distinct mechanism — looks like this:

Radium-223 deserves a specific note, because it shows the difference between sequencing and combining. It is an alpha-emitting agent that homes to bone and, in the ALSYMPCA trial, lengthened survival (14.9 versus 11.3 months) in men with symptomatic bone metastases and no visceral disease.[14] But when it was combined with abiraterone in the ERA-223 trial, it caused more fractures without adding benefit — so the two are not given together, and bone-protective agents (denosumab or zoledronic acid) are used to keep the skeleton safe.[15] Sipuleucel-T, a cellular immunotherapy, lengthens survival in men with few or no symptoms even though it does not lower the PSA — a reminder that not every effective treatment shows up as a falling number.[16] Throughout all of this, bone-protective treatment and good supportive care run quietly in the background.

Where Lu-177 PSMA theranostics fits

Because this is our field, it is worth being precise about where radioligand therapy belongs — and being honest that it is one option among several, not a first move. Lu-177 PSMA-617 (marketed as Pluvicto) is a radioligand: it seeks out the PSMA protein on prostate cancer cells and delivers radiation directly to them. In the VISION trial, given to men with PSMA-positive castration-resistant disease after a hormonal agent and taxane chemotherapy, it improved survival (15.3 versus 11.3 months).[12]

Its place in the sequence is moving earlier. The PSMAfore trial tested it before chemotherapy and more than doubled the time to radiographic progression (12.0 versus 5.6 months), and regulators expanded its approved use in 2025 to selected men who have not yet had a taxane.[13] Two conditions always apply: the cancer must light up on a PSMA-PET scan, and the decision sits within the wider sequence — weighed against chemotherapy, radium-223 and targeted options according to the man’s biology, prior treatment and fitness. For a fuller account, see our pages on Lu-177 PSMA therapy, its success rate, life expectancy and cost, and how it compares with PARP inhibitors.

The logic of age: health status, not the birthday

Prostate cancer is largely a disease of older men, so age threads through every decision above — but not in the way many people assume. The clear message from the Society of Geriatric Oncology (SIOG) is to decide by health status, not chronological age. A fit 78-year-old should be offered the same treatment as a fit 60-year-old; a frail 65-year-old may need a gentler plan than his years suggest.[18]

To make that judgement objective rather than a glance across the consulting room, clinicians use a short screening questionnaire called the G8 (scored 0–17; a score of 14 or below flags the need for a fuller assessment). Where it is abnormal, a comprehensive geriatric assessment looks at other illnesses, nutrition, memory, mood, medications and how independently a man lives. This sorts patients into broad groups — and tailoring treatment to the group, rather than to the calendar, both protects frail men from harm and protects fit men from being under-treated. In one study, a geriatric assessment led to a gentler treatment plan in about 40% of older men without shortening survival.[19]

Age also shapes specific choices. Strong chemotherapy such as docetaxel carries more serious side effects in men over 75, so fitness — not the number — decides whether a triplet is wise.[19] And at the localised stage, a man’s overall life expectancy is one of the main reasons to choose active surveillance over surgery or radiation: if other illnesses are more likely to determine his future than a slow-growing prostate cancer, monitoring is often the kinder and equally safe path.[4]

The principles that tie it all together

Strip away the trial names and the sequence rests on a few durable ideas:

1. Match intensity to the disease and the man. More aggressive cancer, and a fitter patient, justify more aggressive treatment — and the reverse.
2. Intensify early. When disease has spread, adding treatment up front works better than holding drugs in reserve — later lines tend to work less well.
3. Switch the mechanism, don’t repeat it. When a treatment fails, move to one that works a different way rather than a cousin of the one that just failed.
4. Let biology lead. Genetic testing and a PSMA-PET scan increasingly decide which doors are open — PARP inhibitors, immunotherapy, radioligand therapy.
5. Treat the man, not just the cancer. Age, other illnesses, symptoms and personal goals are part of the medicine, not an afterthought.
6. Keep supportive care running. Bone protection and symptom control continue alongside everything else.
7. Decide together. The hardest sequencing calls belong in a multidisciplinary team — and a second opinion is reasonable whenever the path is unclear.